Avectas, ONK to develop cancer cell therapy

By The Science Advisory Board staff writers

May 6, 2020 -- Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy (CAR NK) from ONK Therapeutics for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

The partnership aims to develop a chimeric antigen receptor that uses natural killer cells that are engineered to target specific cancer cells and increase therapeutic potency by adding a secondary cancer cell-killing mechanism using ONK's death receptor (DR5) TRAIL variant. If successful, the off-the-shelf allogeneic therapy would provide transient cell-killing effects in a dose-controlled manner.

Under the collaboration, ONK will accelerate the development of the therapy, incorporating its DR5 TRAIL variant, to a phase I clinical trial. Avectas will engineer the therapy using its nonviral cell engineering platform. Avectas will retain worldwide development and commercialization rights to the therapy.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here